EU/3/12/1055: Orphan designation for the treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)

Belinostat

Overview

On 10 October 2012, orphan designation (EU/3/12/1055) was granted by the European Commission to Topotarget A/S, Denmark, for belinostat for the treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic / disseminated).

The sponsorship was transferred to Onxeo DK Filial af Onxeo S.A., Frankrig, Denmark, in June 2015.

Key facts

Active substance
Belinostat
Intended use
Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)
Orphan designation status
Positive
EU designation number
EU/3/12/1055
Date of designation
10/10/2012
Sponsor
Onxeo DK, Filial af Onxeo S.A., Frankrig
c/o Symbion
Fruebjergvej 3
2100 Copenhagen Ø
Denmark
Tel. +45 3917 9494
Fax +45 3917 9492
E-mail: contact@onxeo.com

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating